Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI study of celecoxib and Layla in healthy volunteers
NCT03553316Phase 1Completed
- Sponsor
- PMG Pharma
- Start
- Feb 2019
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of celecoxib and PG201 in osteoarthritis (OA) (2 arms), sponsored by PMG Pharma. Primary endpoints: Area Under the Curve over the dosing interval at 48 hour and Maximum Plasma Concentration at Steady State at 48 hour. Started Feb 2019; status: completed.
02
Drugs
celecoxibPG201
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03553316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03553316.